Abstract
Background: Lung cancer is the leading cause of cancer death worldwide however no serum marker is routinely recommended till now.Patients and Methods: This is a prospective case control study including two groups of adults, Group I: Includes healthy volunteers as controls. Group II: Includes patients with advanced non-small cell lung cancer (NSCLC). Plasma CA19-9 levels were measured at baseline by ELISA before first line chemotherapy. Primary end point was comparison between the levels of CA19-9 in patients and controls. Secondary endpoint was correlation between CA19-9 level and clinical response (CR), progression free survival (PFS) and overall survival (OS) in advanced NSCLC.Results: 34 healthy adults and 35 patients with advanced NSCLC were included and followed up during the period from October 2009 to February 2013 with median follow up of 10.5 months. The mean and median pre-treatment plasma CA 19-9 concentrations of NSCLC patients were 240.7 and 231U/ml respectively. There was statistically significant difference between the patient and control groups (p < 0.001). No significant correlations were found between CA19-9 levels and CR, PFS and OS p-values: 0.5, 0.3 and 0.6 respectively Conclusion: Plasma CA19-9 is a reliable marker for advanced NSCLC.
Highlights
MethodsThis is a prospective case control study including two groups of adults, Group I: Includes healthy volunteers as controls
Lung cancer is the leading cause of cancer death worldwide no serum marker is routinely recommended till
No significant correlations were found between CA19-9 levels and clinical response (CR), progression free survival (PFS) and overall survival (OS) p-values: 0.5, 0.3 and 0.6 respectively Conclusion: Plasma CA19-9 is a reliable marker for advanced non-small cell lung cancer (NSCLC)
Summary
This is a prospective case control study including two groups of adults, Group I: Includes healthy volunteers as controls. This study was conducted on 69 adults, aged 39-77 years old who were classified into 2 groups; 2.1 Control Group This group constitutes the healthy volunteers who are not complaining of any chronic or acute diseases including any respiratory problems, and who are not on regular medications. Samples were collected from patients presented to chest section of the medical oncology department, National Cancer Institute (NCI), Cairo University, randomly with no selections except for the criteria of having a confirmed diagnosis of NSCLC, and an advanced stage of it (Stage III or IV). We used ELISA to assess CA 19-9 plasma levels
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
